Silence Therapeutics Corp (SLN): חוב לטווח קצר של החברה
Silence Therapeutics (SLN) specializes in developing advanced medical drugs and genetics-based diagnostic systems. The price action reflects the current 0.00 indicator. The firm's environmental policy focuses on purifying laboratory emissions and reducing toxins. Meanwhile, the operating model relies on engaging external research organizations, which are managed by the company's leadership.
SLN (Silence Therapeutics Corp): פילוחים אנליטיים ודוחות לפי אינדיקטורים
The business model of Silence Therapeutics (SLN) is based on licensing revenues from the development of RNA drugs for the treatment of cardiovascular pathologies. By analyzing short-term debt dynamics, an investor assesses the volume of obligations with a maturity of up to twelve months. This metric measures the risk of a liquidity gap by comparing current debts with available liquidity. Low values confirm financial stability, although excessive caution may hinder the scaling of R&D. Market consensus views this indicator as a safeguard against bankruptcy.